Evidence map›Paper›PMID 40872341›Full record

ArticlePathogens (Basel, Switzerland)2025

Susceptibility of

Takashi Yurube, Katsumi Shigemura, Yurino Kobayashi, Taishi Maeda, Nami Nishimura, Ayaka Yamada, Kotoko Kotani, Saki Horii, Hiroyuki Yoshida, Kayo Osawa

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pathogens (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Takashi YurubeDepartment of Orthopaedic Surgery, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan.ORCID 0000-0002-3007-361X
Katsumi ShigemuraDepartment of Urology, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi-Ku, Tokyo 173-8605, Japan.
Yurino KobayashiDepartment of Medical Technology, Faculty of Health Sciences, Kobe Tokiwa University, 2-6-2 Otani-cho, Nagata-ku, Kobe 653-0838, Japan.
Taishi MaedaDepartment of Medical Technology, Faculty of Health Sciences, Kobe Tokiwa University, 2-6-2 Otani-cho, Nagata-ku, Kobe 653-0838, Japan.
Nami NishimuraDepartment of Medical Technology, Faculty of Health Sciences, Kobe Tokiwa University, 2-6-2 Otani-cho, Nagata-ku, Kobe 653-0838, Japan.
Ayaka YamadaDepartment of Medical Technology, Faculty of Health Sciences, Kobe Tokiwa University, 2-6-2 Otani-cho, Nagata-ku, Kobe 653-0838, Japan.
Kotoko KotaniDepartment of Medical Technology, Faculty of Health Sciences, Kobe Tokiwa University, 2-6-2 Otani-cho, Nagata-ku, Kobe 653-0838, Japan.
Saki HoriiDepartment of Medical Technology, Faculty of Health Sciences, Kobe Tokiwa University, 2-6-2 Otani-cho, Nagata-ku, Kobe 653-0838, Japan.
Hiroyuki YoshidaHyogo Clinical Laboratory Corporation, 5-6-2, Aoyamanishi, Himeji 671-2224, Japan.
Kayo OsawaDepartment of Medical Technology, Faculty of Health Sciences, Kobe Tokiwa University, 2-6-2 Otani-cho, Nagata-ku, Kobe 653-0838, Japan.ORCID 0000-0002-4787-4333

Funding

the Research Program on Emerging and Reemerging Infectious Diseases of the Japan Agency for Medical Research and Development, AMED 25fk0108697s0302
6 · The paper itself

Abstract

The DNA synthesis inhibitor zoliflodacin (ZFD) is expected to be effective against strains resistant to therapeutic agents for

Indexed as

Anti-Bacterial AgentsBarbituratesGonorrheaNaphthyridinesNeisseria gonorrhoeaeQuinolonesCeftriaxoneCiprofloxacinDNA GyraseDrug Resistance, BacterialFemaleFluoroquinolonesHumansIsoxazolesJapanMaleAnti-Bacterial AgentsBarbituratesCeftriaxoneCiprofloxacinDNA GyraseFluoroquinolonesIsoxazolesMorpholinesNaphthyridinesOxazolidinonesQuinolonesSpiro CompoundszoliflodacinDNA gyraseNeisseria gonorrhoeaequinolonessusceptibilitytopoisomerase IVzoliflodacin (ZFD)

Identifiers

PMID40872341
PMCPMC12389086

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.